XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
 3 Months Ended
Apr. 29, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Compensation Costs
The stock-based compensation costs that have been charged against income were as follows (in thousands):

13-Weeks Ended
April 29,
2023		April 30,
2022
Stock-based compensation expense by type:
Stock options
$220 $155 
Restricted stock units1,653 2,125 
Employee stock purchases
106 158 
Director deferred compensation26 17 
  Total stock-based compensation expense2,005 2,455 
Income tax benefit recognized454 557 
  Stock-based compensation expense, net of income tax$1,551 $1,898 
Schedule of Equity Awards Granted
We granted the following equity awards:
13-Weeks Ended
April 29,
2023		April 30,
2022
Stock options
8,188 7,212 
Restricted stock unit awards
78,515 107,848 
Performance-based restricted stock unit awards
39,567 49,978 
Deferred stock units
450 405 
Schedule of Stock Options Granted, Exercise Price Per Share and Weighted-average Grant Date Fair Value
Details of stock options granted, exercise price per share and the weighted-average grant date fair value were as follows:

13-Weeks Ended
April 29,
2023		April 30,
2022
Total stock options granted8,188 7,212 
Exercise price$58.38 $46.22 
Fair value of stock options$26.87 $21.46 
Schedule of Shares Purchased The number of shares purchased, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:
13-Weeks Ended
April 29,
2023		April 30,
2022
Shares purchased7,026 14,273 
Average price per share$50.13 $61.14 
Weighted-average fair value at grant date$17.60 $18.03